Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Net margin is calculated as Net Income divided by its Revenue. Labiana Health's Net Income for the
six
months ended in Dec. 2025 was €0.73 Mil. Labiana Health's Revenue for the
six
months ended in Dec. 2025 was €35.98 Mil. Therefore, Labiana Health's net margin for the quarter that ended in Dec. 2025 was 2.03%.
The historical rank and industry rank for Labiana Health's Net Margin % or its related term are showing as below:
XMAD:LAB'
s Net Margin % Range Over the Past 10 Years
Min: -15.46 Med: -1.37 Max: 3.42
Current: 3.42
XMAD:LAB's Net Margin % is ranked worse than 56.76% of 962
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs XMAD:LAB: 3.42
Labiana Health (XMAD:LAB) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Labiana Health Net Margin % Related Terms
Labiana Health Net Margin % Historical Data
* Premium members only.
The historical data trend for Labiana Health's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:LAB vs ZTS, UTHR, VTRS: Net Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Labiana Health's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labiana Health Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Labiana Health's Net Margin % distribution charts can be found below:
* The bar in red indicates where Labiana Health's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Labiana Health (XMAD:LAB) has a Net Margin % of 2.03% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Labiana Health and its competitors. According to the industry distribution chart, Labiana Health ranks #546 out of 962 companies in the Drug Manufacturers industry, placing it in the top 56.8%.
Is Labiana Health's Net Margin % too high?
Labiana Health's current Net Margin % is 2.03%. The Drug Manufacturers industry median Net Margin % is 5.56. Labiana Health's value of 2.03% is 63.5% below this industry median. Based on the distribution chart, Labiana Health ranks #546 out of 962 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Labiana Health has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Labiana Health's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Labiana Health ranks #546 out of 962 companies for Net Margin %. This places Labiana Health in the lower half of its industry. The industry median Net Margin % is 5.56. Labiana Health's value of 2.03% is 63.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Labiana Health's current Net Margin % of 2.03% is 63.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Labiana Health and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labiana Health's current Net Margin % is 2.03%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labiana Health stock overvalued right now?
Based on GuruFocus' analysis, Labiana Health (XMAD:LAB) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.59, compared to a current price of €6.65 — trading 85.2% above its estimated fair value. The current Net Margin % is 2.03% and 63.5% below the Drug Manufacturers industry median of 5.56. Labiana Health's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Labiana Health (XMAD:LAB), the current Net Margin % is 2.03% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Labiana Health (XMAD:LAB) Overvalued in 2026?
Based on GuruFocus' analysis, Labiana Health stock appears to be overvalued.
The current stock price of €6.65 is trading 85.2% above its estimated GF Value™ of €3.59.
GuruFocus considers Labiana Health to be Significantly Overvalued.
Key valuation signals for XMAD:LAB:
Net Margin %: 2.03%
GF Value™: €3.59 vs. price of €6.65 (85.2% above fair value)
Industry Position: 63.5% below the Drug Manufacturers median (#546 of 962)
No single metric tells the full story. See the XMAD:LAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Labiana Health SA is a manufacturer of pharmacological products for veterinary use. The company's activities include a GMP manufacturer for EU animal and human health industries, a manufacturer specializing in sterile and lyophilized dosage forms, and a source of development, acquisition, and licensing of molecules such as Fosfomycin Trometamol. The company operates in two segment Animal Health and Human Health.
57GF Score
Get the complete analysis for XMAD:LAB
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:LAB has been successfully added to your 
